Publications by authors named "Raymond Manuel"

Claim this Profile
C
Correction to: Dose-response effects on HbA and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
Matthias Blüher, Julio Rosenstock, Josef Hoefler, Raymond Manuel, Anita M Hennige

Diabetologia· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-response effects on HbA and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
Matthias Blüher, Julio Rosenstock, Josef Hoefler, Raymond Manuel, Anita M Hennige

Diabetologia· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TRPC6 Inhibitor BI 764198 in Focal Segmental Glomerulosclerosis: Phase 2 Study Design.
Howard Trachtman, Matthias Kretzler, Hailey E Desmond, Wansuk Choi, Raymond C Manuel

Kidney Int Rep· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics/Pharmacodynamics of Dabigatran 75 mg Twice Daily in Patients With Nonvalvular Atrial Fibrillation and Severely Impaired Renal Function.
Jack L Martin, Habib Esmaeili, Raymond C Manuel, Michaela Petrini, Sabrina Wiebe

J Cardiovasc Pharmacol Ther· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial.
James F Donohue, Robert Wise, William W Busse, Sandra Garfinkel, Valentina B Zubek, Raymond C Manuel

BMC Pulm Med· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cause-specific mortality adjudication in the UPLIFT® COPD trial: findings and recommendations.
Lorcan P McGarvey, Sheldon Magder, Deborah Burkhart, Steven Kesten, Dacheng Liu, Raymond C Manuel

Respir Med· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reaction intermediates in the catalytic mechanism of Escherichia coli MutY DNA glycosylase.
Raymond C Manuel, Kenichi Hitomi, Andrew S Arvai, Paul G House, Andrew J Kurtz

J Biol Chem· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis